LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross Sells 3,750 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

LeMaitre Vascular Stock Up 0.2 %

LeMaitre Vascular stock opened at $103.74 on Wednesday. The business has a 50-day simple moving average of $92.45 and a two-hundred day simple moving average of $86.15. The company has a market cap of $2.33 billion, a P/E ratio of 56.69, a P/E/G ratio of 2.50 and a beta of 0.89. LeMaitre Vascular, Inc. has a 52-week low of $51.70 and a 52-week high of $106.49.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 EPS. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be paid a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.62%. LeMaitre Vascular’s dividend payout ratio is currently 34.97%.

Analyst Ratings Changes

Several research firms have recently issued reports on LMAT. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target for the company. StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Cantor Fitzgerald began coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target for the company. Finally, Barrington Research lifted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Glenmede Trust Co. NA grew its stake in shares of LeMaitre Vascular by 1.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock valued at $976,000 after acquiring an additional 136 shares during the period. Summit Global Investments grew its stake in shares of LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after acquiring an additional 146 shares during the period. Shaker Investments LLC OH grew its stake in shares of LeMaitre Vascular by 1.3% during the 2nd quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock valued at $1,138,000 after acquiring an additional 175 shares during the period. NBC Securities Inc. grew its stake in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 188 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.